摘要
目的 探讨杏芎氯化钠注射液联合盐酸阿罗洛尔片治疗不稳定型心绞痛(unstable angina pectoris,UAP)的效果。方法选取2018年8月至2021年8月我院UAP患者92例,随机分为观察组和对照组,各46例。两组均给予基础治疗,对照组服用盐酸阿罗洛尔片治疗,观察组服用盐酸阿罗洛尔片的同时给予杏芎氯化钠注射液治疗。治疗2周后评价治疗效果,统计治疗期间不良反应发生率。治疗前、治疗1及2周后统计两组心绞痛发作情况,并检测心功能、氧化-抗氧化指标、基质细胞衍生因子-1(SDF-1)及趋化因子受体7(CXCR7)。结果 两组疗效评估结果显示,观察组较对照组高(P<0.05);治疗1及2周后,观察组心绞痛发作频次、持续时间、视觉模拟量表评分及每周硝酸甘油用量低于对照组,左心室射血分数、心脏指数及每搏输血量高于对照组(P<0.05);治疗1及2周后,观察组丙二醛、过氧化脂质、SDF-1及CXCR7低于对照组,超氧化物歧化酶高于对照组(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论 杏芎氯化钠注射液联合盐酸阿罗洛尔片能减轻UAP患者心绞痛发作情况,改善心功能,恢复氧化-抗氧化平衡,调节SDF-1、CXCR7,效果显著,且安全性高。
Objective To explore the effect of Xingxiong sodium chloride injection combined with arotinolol hydrochloride tablets in the treatment of unstable angina pectoris(UAP).Methods A total of 92 UAP patients in our hospital from August 2018 to August 2021 were randomly divided into observation group and control group,with 46 cases in each group.Both groups were given basic treatment,the control group was given arotinolol hydrochloride tablets,and the observation group was treated with Xingxiong sodium chloride injection combined with arotinolol hydrochloride tablets.Treatment effect was evaluated after 2 weeks of treatment.The incidence of adverse reactions during the treatment period was calculated.Angina pectoris were counted before treatment,1 week and 2 weeks after treatment in the two groups.Heart function,oxidation-antioxidant indexes,stromal cell-derived factor-1(SDF-1),chemokine receptor 7(CXCR7) were measured.Results The efficacy evaluation results of the two groups showed that the observation group was higher than the control group(P0.05).Conclusion Xingxiong sodium chloride injection combined with arotinolol hydrochloride tablets can alleviate angina pectoris attack in UAP patients,improve heart function,restore oxidation-antioxidant balance,regulate SDF-1 and CXCR7 with significant effects and high safety.
作者
张伟
胡金涛
杨思共
户学敏
ZHANG Wei;HU Jintao;YANG Sigong;HU Xuemin(Department of Cardiology,Suzhou First People's Hospital,Suzhou 234099,Anhui Province,China)
出处
《世界临床药物》
CAS
2022年第8期1044-1050,共7页
World Clinical Drug
基金
宿州市科学技术局[宿科(2016)20号]。
